Actively Recruiting
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Led by Ribocure Pharmaceuticals AB · Updated on 2026-03-12
120
Participants Needed
4
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.
CONDITIONS
Official Title
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to comply with visit schedule and provide written informed consent
- Male or female participants aged 18 to 80 years inclusive
- Fasting triglyceride level of 150 to less than 499 mg/dL
- Fasting non-HDL cholesterol level at least 100 mg/dL, or LDL cholesterol at least 70 mg/dL after stable diet and optimal statin therapy for at least 4 weeks if indicated
- Body mass index between 18 and 40 kg/m2
You will not qualify if you...
- Any uncontrolled or serious disease or medical/surgical condition that may interfere with participation or pose significant risk
- Uncontrolled hypertension with blood pressure over 160/100 mmHg at screening (may be re-screened if treated and controlled)
- Active or history of serious mental illness requiring current medication, including schizophrenia, bipolar disorder, or severe depression
- Liver enzyme levels ALT or AST more than twice the upper limit of normal at screening
- Kidney function eGFR below 30 mL/min/1.73 m2 at screening
- HbA1c above 9.0% (or above 75 mmol/mol IFCC units) at screening
- Diagnosis of hepatitis B, hepatitis C, or HIV at screening
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Lunds Universitetssjukhus
Lund, Sweden
Actively Recruiting
2
Ribocure Clinic/Ribocure Pharmaceuticals AB
Mölndal, Sweden
Actively Recruiting
3
AkardoMedSite
Stockholm, Sweden
Actively Recruiting
4
Akademiska Sjukhuset Uppsala
Uppsala, Sweden
Actively Recruiting
Research Team
R
Rebeckha Magnusson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here